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Purpose of review: PARP inhibitors have transformed the management of BRCA mutant 
(BRCAmut) high-grade serous and endometroid ovarian cancer (HGOC). However, it is clear 
the benefit can be extended beyond this subgroup, particularly to those cancers with 
homologous recombination repair deficiency (HRD). We review emerging molecular and 
clinical data to support the use of PARP inhibitors in HRD HGOC and discuss the advantages 
and disadvantages of different HRD assays.  
Recent Findings: Several phase 3 trials support the use of PARP inhibitor maintenance 
therapy beyond those patients with BRCAmut in the first-line and platinum sensitive relapse 
setting. Many of these studies included HRD testing and it is clear, regardless of the assay 
used, that an incremental reduction in benefit is observed from BRCAmut tumours to HRD to 
homologous recombination proficient tumours. However, whilst currently available HRD 
assays predict the magnitude of benefit from PARP inhibitors, they consistently fail to identify 
a sub-group of patients who do not benefit.   
Summary: Clinical data supports the use of PARP inhibitor maintenance therapy beyond 
BRCAmut patients. Current HRD tests lack negative predictive value and more research is 
required to develop a composite HRD assay which provides a dynamic readout of HRD status. 





PARP inhibitors represent the biggest breakthrough in the systemic treatment of the most 
common and most lethal forms of ovarian cancer (high grade serous and endometroid, HGOC) 
in the last 20 years. In patients whose tumours harbour a BRCA1 or BRCA2 mutation 
(BRCAmut), PARP inhibitor maintenance therapy produces an unprecedented progression free 
survival (PFS) benefit in the first-line and relapsed disease settings (1-5). PARP inhibitor use 
can even result in long term (>6 year) remission for some patients with relapsed disease (6). 
The key to this sensitivity is believed to be the homologous recombination deficiency (HRD) 
which is typified by the lack of a functional copy of either BRCA1 or BRCA2. However, the 
BRCA genes can by inactivated by non-mutational processes and there are many other 
proteins involved in homologous recombination repair (HRR) whose loss can also confer an 
HRD phenotype. PARP inhibitor studies in patients whose tumours do not harbour a BRCAmut 
also demonstrate evidence of significant efficacy (2, 4, 7-10) but strategies for accurate patient 
selection remain elusive. In this review we discuss from the molecular and clinical perspectives 
the importance of homologous recombination repair in ovarian cancer, the advantages and 
disadvantages of the various HRD assays and additional factors that contribute to the 
assessment of HRD in patients being considered for PARP inhibitor therapy. 
Homologous recombination repair (HRR) 
HRR is a process conserved in evolution from bacteria to humans which facilitates the 
exchange of genetic information and within the cancer context allows the repair of breaks in 
double stranded DNA with the use of a template, thus maintaining the integrity of the 
sequence. Some of the key genes which when disrupted or dysregulated result in homologous 
recombination deficiency are shown in Figure 1. These include: BRCA1 and BRCA2; genes 
that are less commonly disrupted but still responsible for hereditary cancer such as BARD1, 
BRIP1 and PALB2; (11, 12) RAD family genes; (11-13) HR-related genes such as EMSY, 
CHEK1 or CHEK2; (11-13) genes involved in activating the DNA damage response such as 
ATM, ATR and ATX; (11, 13) and the Fanconi anaemia genes (13). 
The efficacy of PARP inhibitors is primarily related to their ability to trap PARP on DNA strands. 
When replication forks meet trapped PARP they stall and in the absence of functional HRR 
they collapse (14). This results in double-stranded DNA breaks which in HRD cells have to be 
dealt with by error-prone DNA repair mechanisms such as non-homologous end-joining or 
microhomology-mediated repair (15). 
 
Homologous recombination deficiency in ovarian cancer  
The reason why PARP inhibition has been particularly successful in HGOC relates to the 
biology of this disease. Rather than being characterised by oncogene activation, HGOC has 
almost ubiquitous TP53 mutation (16), which in turn allows the cancer cells to tolerate DNA 
repair deficiencies, copy number abnormalities and multiple large chromosomal structural 
variants (Figure 2) (17) without undergoing cell cycle arrest or apoptosis. Indeed, 
approximately half of all HGOCs have molecular aberrations which have the potential to confer 
HRD (Figure 2). Germline and somatic BRCAmut when combined account for almost half of 
these HRD HGOC cases. The rest are made up by methylation of BRCA1 and RAD51C, 
amplification or overexpression of EMSY and non-BRCA HR gene mutations. Similarly, 
although case numbers are smaller, there is a suggestion from clinical studies that RAD51C 
methylation confers PARP inhibitor sensitivity (18) but the role of EMSY in HRD is less clear 
(19). The remaining small percentage of HRD HGOC cases are made up of mutations in minor 
HR genes, RAD family genes, HR related genes, DNA damage response genes and Fanconi 
anaemia genes outlined in Figure 1. 
 
Strategies to determine HRD status in BRCA wild-type tumours 
Strategies to select HGOC patients with BRCAwt tumours who are most likely to benefit from 
PARP inhibition can be grouped into four main categories: clinical; functional; 
sequence/epigenetic and DNA ‘scarring’ assays. 
Clinical selection of patients who had responded to multiple lines of platinum-based 
chemotherapy was utilised in relapsed disease PARP inhibitor studies on the basis that HRD 
confers platinum sensitivity for similar biological reasons that allow it to confer PARP inhibitor 
sensitivity. However, multiple in vitro and in vivo studies have demonstrated that the overlap 
between PARP inhibitor and platinum resistance is incomplete and vice versa (20-22). 
Functional assays rely upon assessing whether cells have the capacity for HRR. In theory this 
is an excellent strategy because it determines the actual HRD status of the cells at that point 
in time rather than a molecular change or a genomic scar either of which could have been 
subsequently rendered irrelevant by mechanisms of resistance. The assays utilised to date 
have been cumbersome, requiring in vitro culture of tumour cells followed by assessment for 
gammaH2AX and Rad51 focus formation following PARP inhibitor exposure. However, they 
have demonstrated promise in terms of capacity to determine PARP inhibitor sensitivity (23). 
A recent study performing the RAD51 assessment in formalin fixed paraffin embedded 
material suggests that this may be more predictive of PARP inhibitor sensitivity than 
sequencing, epigenetic studies and scarring assays (24). 
Although sequencing to detect genetic mutations or epigenetic changes in HRD genes can 
easily be done, it has become clear that some patients with HGOC have a good response to 
PARP inhibitors with no discernible mutational event (25, 26). This suggests there are some 
HRD mechanisms that we cannot presently explain. 
Genomic scarring assays, like functional assays do not require an understanding of the 
underlying molecular cause of the HRD, they simply detect that it exists. The commercial 
assays that have been primarily used in ovarian cancer studies to date are the Foundation 
Medicine loss of heterozygosity (LOH) assay (2, 18, 26) and the Myriad MyChoice assay (4, 
7, 8, 10, 26). These assays generate a score based upon the extent of LOH (Foundation 
Medicine) or a combination of LOH, large scale transitions and telomeric imbalance (Myriad 
MyChoice). The benefit of these assays is that they cover a variety of molecular causes of 
HRD. The disadvantage is that they only determine that there was HRD present at some point 
in time, and not necessarily that it is currently present. For example, if the tumour cell was 
initially HRD but developed a resistance mechanism restoring HRR, the same score from the 
genomic scarring assays would be obtained and the restoration would not be detectable (false 
positive issue). In addition, it is clear from some of the key PARP inhibitor clinical trials that 
there are patients who are homologous recombination proficient (HRP) by the scarring assays 
and yet benefit from PARP inhibition (false negative issue) (2, 4, 8). 
Although a full discussion of the mechanisms of PARP inhibitor resistance are beyond the 
scope of this review (comprehensively outlined by Mateo et al) (27), it is clear that a better 
understanding of these is key to improving our selection of patients for PARP inhibitor therapy. 
The resistance mechanisms can be separated into two main groups. The first involves 
changes that restore HRR, either through re-expression of a gene that was mutationally or 
epigenetically silenced or through rewiring of the DNA damage response. In these cases, 
sequencing of archival material or scarring assays could be misleading if the resistance event 
is not detected. The second group of resistance mechanisms do not result in restoration of 
HRR and includes processes such as reduction in PARP trapping, (28, 29) replication fork 
protection (30, 31) and increased drug efflux (22). 
Clinical evidence for efficacy beyond BRCA  
Recurrent disease  
The initial phase I/II studies with olaparib in BRCAmut tumours showed there was a relationship 
between the response in HGOC and ‘platinum-sensitivity’ of the tumour, as determined by the 
platinum-free interval before PARP inhibitor therapy (21). It was therefore hypothesised that 
HGOC that did not have either a germline or somatic BRCAmut might also respond to PARP 
inhibition. In a phase II trial with olaparib 24% (11 out of 46) of patients with HGOC without a 
BRCAmut responded (32). Again, most but not all the responses were seen in tumours 
classified as ‘platinum-sensitive’. 
The hypothesis was explored further in a randomised phase II trial in which patients with 
HGOC who responded to platinum-based therapy were randomised to maintenance with 
olaparib capsules or placebo. The trial explored the concept of using maintenance therapy to 
improve clinical benefit, determined by prolongation of PFS. A response to platinum-based 
therapy in patients with recurrent HGOC was used to enrich the population likely to benefit. In 
‘study 19’ 22% were known to have a BRCAmut, 14% were BRCAwt and 63% had an unknown 
BRCA status. In this trial the median PFS was prolonged from 4.8 to 8.4 months after the start 
of trial treatment (HR 0.35 95% CI 0.25-0.49; P < 0.001) (9). Subsequent analysis of BRCA 
status was undertaken in the BRCA unknown group and BRCA status became available in 
96% of the 256 patients enrolled in the trial. The greatest benefit in PFS maintenance with 
olaparib compared to placebo was seen in the BRCAmut group (HR 0.18; 95% CI 0·10–0·31; 
p<0·0001). However, in the 118 BRCAwt patients there was also a significant PFS benefit (HR 
0·54; 95% CI 0·34–0·85; p=0·0075) (3). Subsequent phase III trials with the PARP inhibitors, 
niraparib (NOVA) and rucaparib (ARIEL3) included patients without a BRCA mutation and 
both studies showed significant benefit in the non-BRCAmut group (2, 4) (Table1). Both these 
trials subdivided patients without a BRCA mutation in HRD or HRP based on the Myriad or 
Foundation Medicine HRD assays but these tests were not able to identify sub populations 
(eg HRP) that did not benefit from maintenance therapy with a PARP inhibitor (2, 4). The false 
negative rate in this setting, may have been contributed to by the fact that these patients were 
highly selected for platinum sensitivity, which is in itself a strong marker for HRD. Olaparib, 
niraparib and rucaparib are now all licensed as maintenance treatment in high grade recurrent 
ovarian cancers that have responded to platinum-based therapy, irrespective of BRCA status 
and these drugs are now accepted as a standard of care in recurrent ovarian cancer. 
First-Line Maintenance Therapy   
Recent evidence supports maintenance PARP inhibitor use in the first-line setting following 
cytoreductive surgery and platinum-based chemotherapy (1, 8, 10, 33). The introduction of 
olaparib maintenance following chemotherapy in BRCAmut ovarian cancer led to an 
unprecedented improvement with a 70% reduction in the risk of disease progression or death 
compared to placebo (60 vs 27% HR 0.30, 95% CI 0.23-0.41) (1). Three further randomised 
phase 3 trials, PRIMA, PAOLA1 and VELIA, have evaluated first-line maintenance PARP 
inhibitors in BRCAwt patients and suggest that BRCAwt/HRD tumours may also benefit, 
although to a lesser degree than the BRCAmut population (Table 1) (8, 10, 33). In each of these 
trials, BRCAmut consistently predicted PARP inhibitor benefit with a similar magnitude to that 
seen in the relapsed setting (HR range 0.31-0.44) (1, 8, 10, 33).  
The PRIMA study compared niraparib and placebo with patients stratified by HRD-score 
(Myriad). BRCAwt /HRD patients benefited from niraparib with a PFS increase from 8.2 to 19.6 
months (HR; 0.5, 95% CI 0.31-0.83). The trial was not powered to detect benefit in the HRP 
subgroup although exploratory analyses indicate some benefit, albeit of a lesser magnitude 
(HR 0.68; 95%CI 0.49-0.94) (8). The PAOLA-1 study investigated the addition of olaparib or 
placebo to bevacizumab maintenance (stratified by tumour BRCA status) (10). The HRD score 
differentiated between BRCAwt tumours that derived benefit (HRD HR 0.43; 95% CI 0.28-0.66) 
and no benefit (HRP HR 0.92; 95% CI 0.72-1.17) from the addition of olaparib (1, 8, 10, 33). 
In contrast, exploratory analysis within the VELIA study, suggested less benefit in BRCAwt 
tumours from the addition of veliparib given with chemotherapy and as maintenance therapy, 
whether HRD (HR 0.80; 95%CI 0.64-0.997) or HRP (HR; 0.81; 95% CI 0.6-1.09) (33). Patients 
were enrolled at diagnosis and not following a selection of patients responding to initial 
treatment as in PRIMA and PAOLA-1 (1, 8, 10, 33). Secondly, an unvalidated HRD cut off 
score (Myriad) was used making it harder to draw meaningful conclusions from these data.  
PARP inhibitor Monotherapy  
Olaparib and rucaparib have monotherapy licences for recurrent BRCAmut ovarian cancer with 
overall response rates (ORR) of 31-41% and up to 53.8% respectively (32, 34-37). Currently 
there are limited opportunities to use a PARP inhibitors as monotherapy for BRCAwt tumours, 
despite an ORR for olaparib of 24% in BRCAwt  tumours and 44% for rucaparib in BRCAwt/HRD 
tumours (18, 32) Niraparib is the only drug approved (in the USA) for monotherapy in a heavily 
pre-treated (3 lines) BRCAwt/HRD population following an ORR of 24% in the QUADRA trial 
(38, 39). 
Combination therapy  
Combining PARP inhibitors with other agents may increase benefit, particularly in non-BRCA 
or HRP patients. Whilst combining PARP inhibitors with DNA-damaging chemotherapy is 
appealing due to potential synergy, overlapping toxicity especially myelosuppression, limits 
this combination (40, 41). More appealing is the combination of PARP inhibitors with other 
inhibitors of DNA repair, angiogenesis and cell cycle as well as immune checkpoint inhibitors 
(Tables 1 and 2). These combinations have the potential to increase clinical synthetic lethality, 
or alternatively act by independent mechanisms without overlapping toxicity. Whilst an in-
depth review of PARP inhibitor combination therapy is outside the scope of this review, the 
two most evaluated combinations are discussed briefly, and further ongoing studies listed in 
Table 2.  
Preclinical studies suggest that augmentation of hypoxia with drugs such as cediranib may 
reduce the expression of key HR proteins and sensitise to PARP inhibition, and forms the 
basis of many ongoing studies (42, 43). The addition of cediranib to olaparib versus olaparib 
alone in patients with relapsed HGOC increased PFS (17.7 versus 9.0 months) (43), with the 
greatest benefit in the BRCAwt group (23.7 versus 5.7 months) (44). Whether this combination 
is superior to chemotherapy for recurrent disease is under evaluation (Table 2), and the value 
of this combination as maintenance therapy is being investigated within ICON9 
(NCT03278717). The AVANOVA trial compared niraparib versus niraparib and bevacizumab 
as a treatment strategy; demonstrating improved PFS in the intention-to-treat population 
(irrespective of HRD), as well as in the BRCAwt group but not the BRCAmut group (Table 1) 
(45).  
Preliminary results from early-phase trials demonstrate activity for the combination of PARP 
inhibitors with immune checkpoint inhibitors, with ORR in HGOC between 18-72% (46, 47). 
The rationale for this combination is based on two hypotheses. HRD cancers have a higher 
tumour mutational burden leading to elevated neo-antigen loads, which is thought to stimulate 
an increased anti-tumour immune response (48, 49). Secondly, treatment with PARP 
inhibitors upregulates PD-L1 expression in vivo and in vitro (50), and in the absence of a 
functional BRCA pathway there is activation of the innate immune response via the 
STING/TKB1/IRF3 response (51), which may augment the antitumour effect of the 
combination. The combination of niraparib and pembrolizumab in a predominately platinum-
resistant (76%) population was tolerable with an ORR of 18%, with similar ORR regardless of 
HRD or BRCAmut status (Table 1) (47). The ongoing MEDIOLA trial is evaluating olaparib and 
durvalumab as a chemotherapy sparing regimen for platinum-sensitive recurrent disease in 
both BRCAmut and BRCAwt populations. Within the BRCAmut cohort, interim results suggest an 
ORR of 71.9% (95% CI: 53-86) (46). The results in the BRCAwt population are awaited and 
several trials combining PARP inhibitors with immune checkpoint inhibitors are underway 
(Table 2).  
Conclusion  
Clinical data supports the use of PARP inhibitor maintenance therapy beyond BRCAmut 
patients in both the relapsed and first-line setting. In relapsed disease platinum-sensitivity is a 
good marker for PARP inhibitor response with current HRD assays failing to improve on this, 
as they do not reliably identify a sub-group of patients who will not benefit. However, as PARP 
inhibitor therapy use in first-line maintenance setting increases there is an urgent need for 
better HRD assays in the BRCAwt population as assessment of platinum-sensitivity may be 
unclear following complete resection of disease at surgery. HRD tests are needed to help 
evaluate combination therapies with anti-angiogenic drugs and immune checkpoint inhibitors 
as platinum-sensitivity assessments may not apply in these patients. However, the molecular 
and genomic alterations leading to an HRD phenotype are complex, and more research is 
needed to develop a composite HRD assay to provide a dynamic readout of HRD status. 
 
Key points:  
 PARP inhibitors have transformed the management of BRCAmut HGOC. 
 Clinical data demonstrates that this benefit extends beyond BRCAmut cancers, 
particularly in those cancers characterised by homologous recombination deficiency.  
 A variety of strategies exist to select BRCAwt tumours who are most likely to benefit 
from PARP inhibition can these can be grouped into one of four categories: clinical; 
functional; sequence/epigenetic and DNA ‘scarring’ assays. 
 Whilst currently available HRD assays predict the magnitude of benefit from PARP 
inhibitors, they consistently fail to identify a sub-group of patients who will not benefit.   
 Ongoing research is required to develop a composite HRD assay which provides a 
dynamic readout of HRD status and allows stratification of patients to maximise benefit 
from PARP inhibitor treatment. 
 
Figure and Table Legends 
Figure 1: Targets of genomic disruption related to homologous recombination 
deficiency. Other RAD family members include genes such as RAD52 and RAD54L. Other 
FANC family members encode other subunits of the Fanconi Anaemia core complex, and 
related proteins. 
Figure 2: Onion plot showing molecular subgroups of HGSOC. Core: ubiquitous p53 
inactivation. Layer 1: homologous recombination proficient tumours, including CCNE1 
amplified cases. Layer 2: homologous recombination deficient tumours. Outer layer: tumour 
suppressor genes frequently inactivated by structural variants. 
Table 1: Key randomised controlled trials of PARP inhibitor maintenance therapy and 
combination therapy in HGOC.  Benefit from PARP inhibitor is displayed as progression free 
survival (PFS) or overall response rate (ORR) with corresponding hazard ratios (HR) and 95% 
confidence intervals (CI). Primary analyses are in black font with exploratory analyses in grey. 
Key: HRD = homologous recombination deficiency, BRCAmut = mutation in BRCA1 or BRCA2 
gene, BRCAwt = BRCA1 /2 wild-type, g = germline, ITT = intention to treat, LOH – loss of 
heterozygosity score, NR = not reached.  
Table 2: PARP inhibitor combination trials in progress. Key: HRD = homologous 
recombination deficiency, BRCAmut = mutation in BRCA1 or BRCA2 gene, BRCAwt = BRCA1 
/2 wild-type, ATMmut = mutation in ATM, SOC = standard of care  
 
Acknowledgements. None  
Financial support and sponsorship.   
CG: Charlie Gourley’s laboratory is supported by the Nicola Murray Foundation, Target 
Ovarian Cancer and Cancer Research UK. 
REM: none 
RH: Robert Hollis is supported by funding from Target Ovarian Cancer. 
JAL: none 
 
Conflicts of interest  
CG: Research  funding  from  AstraZeneca,  Aprea,  Nucana,  Tesaro, GSK  and Novartis;  
honoraria/consultancy  fees  from  Roche,  AstraZeneca,  Tesaro,  GSK, Nucana,  MSD,  
Clovis, Foundation  One,  Sierra  Oncology  and  Cor2Ed;  named  on  issued/pending  patents  
relating  to predicting treatment response in ovarian cancer unrelated to this work. 
REM: consultancy fees from Merck, Tesaro-GSK and Clovis Oncology, speaker bureau from 
Roche and Tesaro-GSK and travel grants from AstraZeneca and Tesaro-GSK.  
RH: none 
JAL: Advisory Boards and Lectures for AstraZeneca; Clovis Oncology; GSK. Advisory Boards 




1. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance 
Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. The New England journal of 
medicine. 2018;379(26):2495-505.  
* First study of PARP maintenance in the first line setting in BRCA mutated patients demonstrating an 
unprecidented improvement in PFS 
2. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib 
maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): 
a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949-61.  
3. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib 
maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a 
preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet 
Oncol. 2014;15(8):852-61.  
4. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib 
Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. The New England journal of 
medicine. 2016;375(22):2154-64. 
5. Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib 
tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a 
BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 
trial. Lancet Oncol. 2017;18(9):1274-84. 
6. Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, et al. Long-Term 
Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular 
Characterization. Clin Cancer Res. 2017;23(15):4086-94. 
7. Coleman RL, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Post hoc exploratory 
analysis of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma from the 
randomized, placebo-controlled phase III study ARIEL3: Effect of a deleterious germline or no 
germline BRCA mutation on efficacy Gynecol Oncol. 2019;154 Suppl 1:237. 
8. Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. 
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. The New England journal of 
medicine. 2019;381(25):2391-402.  
** Randomised phase 3 trial demostrating benefit of 1st line niraparib in all ITT population. Incremental 
reduction in benefit from BRCA to HRD to HRP 
9. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib 
maintenance therapy in platinum-sensitive relapsed ovarian cancer. The New England journal of 
medicine. 2012;366(15):1382-92. 
10. Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al. Olaparib 
plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. The New England journal of 
medicine. 2019;381(25):2416-28.  
** Randomised phase 3 trial demonstrating benefit of adding olaparib to bevacizumab to 1st line in 
BRCAmutant and HRD populations  
11. Garsed DW, Alsop K, Fereday S, Emmanuel C, Kennedy CJ, Etemadmoghadam D, et al. 
Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are 
Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. Clin Cancer Res. 
2018;24(3):569-80. 
12. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes 
for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel 
sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032-7. 
13. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. 
Nature. 2011;474(7353):609-15. 
14. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 
and PARP2 by Clinical PARP Inhibitors. Cancer research. 2012;72(21):5588-99. 
15. Friedberg EC. A brief history of the DNA repair field. Cell Res. 2008;18(1):3-7. 
16. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver 
mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 
2010;221(1):49-56. 
17. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. 
Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489-94. 
18. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, 
platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-
label, phase 2 trial. Lancet Oncol. 2017;18(1):75-87. 
19. Hollis RL, Churchman M, Michie CO, Rye T, Knight L, McCavigan A, et al. High EMSY 
expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged 
survival and hypersensitivity to platinum. Cancer. 2019;125(16):2772-81. 
20. Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, et al. Efficacy of 
chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: 
a multi-institutional study. Clin Cancer Res. 2013;19(19):5485-93. 
21. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-
ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating 
with platinum-free interval. J Clin Oncol. 2010;28(15):2512-9. 
22. Vaidyanathan A, Sawers L, Gannon AL, Chakravarty P, Scott AL, Bray SE, et al. ABCB1 
(MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant 
ovarian cancer cells. Br J Cancer. 2016;115(4):431-41. 
23. Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, et al. 
Development of a functional assay for homologous recombination status in primary cultures of 
epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin 
Cancer Res. 2010;16(8):2344-51. 
24. Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutierrez-Enriquez S, Ducy M, Ibrahim YH, 
et al. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA 
mutation. EMBO Mol Med. 2018;10(12). 
25. Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, et al. Long-term 
efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade 
serous ovarian cancer treated with maintenance olaparib capsules following response to 
chemotherapy. Br J Cancer. 2018;119(9):1075-85. 
26. Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, et al. Candidate 
biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. Br J Cancer. 
2018;119(11):1401-9. 
27. Mateo J, Lord CJ, Serra V, Tutt A, Balmana J, Castroviejo-Bermejo M, et al. A decade of 
clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30(9):1437-47. 
* Comprehensive review of PARP inhibitors  
28. Herzog M, Puddu F, Coates J, Geisler N, Forment JV, Jackson SP. Detection of functional 
protein domains by unbiased genome-wide forward genetic screening. Sci Rep. 2018;8(1):6161. 
29. Pettitt SJ, Krastev DB, Brandsma I, Drean A, Song F, Aleksandrov R, et al. Genome-wide and 
high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor 
resistance. Nat Commun. 2018;9(1):1849. 
30. Rondinelli B, Gogola E, Yucel H, Duarte AA, van de Ven M, van der Sluijs R, et al. EZH2 
promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 
trimethylation. Nat Cell Biol. 2017;19(11):1371-8. 
31. Taglialatela A, Alvarez S, Leuzzi G, Sannino V, Ranjha L, Huang JW, et al. Restoration of 
Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork 
Remodelers. Mol Cell. 2017;68(2):414-30 e8. 
32. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in 
patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative 
breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 
2011;12(9):852-61. 
33. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. 
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. The New 
England journal of medicine. 2019;381(25):2403-15.  
** Randomised phase 3 trial demostrating benefit of 1st line velaparib BRCA mutant and HRD 
populations 
34. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et 
al. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. J 
Clin Oncol. 2015;33(3):244-50. 
35. Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, et al. Antitumor 
activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and 
a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and 
ARIEL2. Gynecol Oncol. 2017;147(2):267-75. 
36. FDA U. FDA approval of olaprib 2017 [Available from: 
https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm572143.htm. 
37. FDA U. FDA approval of rucaparib monotherapy 2017 [Available from: 
https://www.fda.gov/drugs/resources-information-approved-drugs/rucaparib. 
38. Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib 
monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-
arm, phase 2 trial. Lancet Oncol. 2019;20(5):636-48. 
39. FDA U. FDA approval of niraparib monotherapy for ovarain cancer FDA; 2020 [cited 2020 20 
April 2020]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-
approves-niraparib-hrd-positive-advanced-ovarian-cancer. 
40. Del Conte G, Sessa C, von Moos R, Vigano L, Digena T, Locatelli A, et al. Phase I study of 
olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J 
Cancer. 2014;111(4):651-9. 
41. van der Noll R AJE, Jager A,  Marchetti S, Mergui-Roelvink M, De Bono J.S, Lolkema M, 
Brunetto A,  Arkenau H.T,  De Jonge M.J,  van der Biessen D, Tchakov I, Bowen K,  Schellens JHN;. 
Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced 
solid tumors. J Clin Oncol (Meeting Abstracts). 2013;31(15_suppl):2579. 
42. Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, et al. Cediranib suppresses homology-
directed DNA repair through down-regulation of BRCA1/2 and RAD51. Sci Transl Med. 2019;11(492). 
* Pre-clincal rationale for combining cediranib and PARP  
43. Liu JF, Barry WT, Birrer M, Lee J-M, Buckanovich RJ, Fleming GF, et al. Combination 
cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian 
cancer: a randomised phase 2 study. The lancet oncology. 2014;15:1207-14. 
44. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Overall survival and 
updated progression-free survival outcomes in a randomized phase II study of combination cediranib 
and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 
2019;30(4):551-7. 
45. Mirza MR, Avall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, et al. 
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer 
(NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 
2019;20(10):1409-19. 
46. Drew Y KB, Banerjee S, Lortholary A, Hong SH, YPark YH, Zimmermann S, Roxburgh P, 
Ferguson M, Alvarez RH, Domchek S, Gresty C, Angell HK, Rocher Ros V, Meyer K, Lanasa M, 
Herbolsheimer P, de Jonge M. Phase II study of olaparib + durvalumab (Mediola): Updated results in 
germline BRCA-mutated platinum-sensitive relapsed (psr) ovarian cancer (oc). Annals of Oncology. 
2019;30 v475-v532. 
47. Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, et al. 
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With 
Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019. 
48. Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, et al. CTLA-4 
Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. 
Cancer Immunol Res. 2015;3(11):1257-68. 
49. Huang J, Wang L, Cong Z, Amoozgar Z, Kiner E, Xing D, et al. The PARP1 inhibitor BMN 673 
exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. Biochem Biophys 
Res Commun. 2015;463(4):551-6. 
50. Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, et al. PARP Inhibitor Upregulates 
PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 
2017;23(14):3711-20. 
51. Parkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, et al. Activation of 
STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. J 
Natl Cancer Inst. 2017;109(1). 
 
NCT number and 
Trial Name 
NCT02446600    
NRG-GY004 



















Immune Check-Point Inhibitors 
NCT03326193 
OVARIO
PARP inhibitor Combination Comparator
olaparib cediranib olaparib single agent vs carboplatin based chemotherapy
olaparib cediranib olaparib single agent vs SOC chemotherapy















Maintainence therapy:     
placebo/placebo vs         
niraparib/placebo vs 
niraparib/dostarlimab                             
+/- bevacizumab as SOC
NAniraparib bevacizumab
Indication Patient population Phase
platinum sensitive disease Any BRCA/HRD 3
platinum resistant disease Any BRCA/HRD 3
platinum resistant disease Any BRCA/HRD 2
maintenance following response to 
platinum chemotherapy for relapsed 
disease
Any BRCA/HRD 3
platinum sensitive BRCAmut and BRCAwt cohorts 2
platinum sensitive BRCAmut or ATMmut 2
platinum sensitive Any BRCA/HRD 1 and 2
maintenance following first line 
chemotherapy Any BRCA/HRD 3
durvalumab/placebo with concurrent 
chemotherapyand bevacizumab followed 
by maintenance therapy first line 
Any BRCA/HRD 3
dostarlimab/placebo with concurrent 
chemotherapy followed by maintenance 
therapy first line 
Any BRCA/HRD 3
maintenance following first line 
chemotherapy 
high grade serous or 
BRCAmut 2
Study
SOLO2 (NCT01874353)  






Coleman et al, NEJM, 2019
ARIEL3 (NCT01968213) 
Coleman et al. Lancet, 
2017
Maintenan             
PAOLA-1 (NCT02477644) 
Ray-Coquard et al. Annals 
of Oncology, 2019
     
NOVA (NCT01847274) 
Mirza et al. NEJM, 2016
Study19 (NCT00753545) 
Ledermann et al. Lancet 
Oncol, 2014
SOLO1 (NCT01844986) 
Moore et al.NEJM, 2018
  TOPACIO (NCT02657889) 
Konstantinopoulos et al. 
JAMA Oncology , 2019
NCT0111648                   Liu 
et al. Annals of Oncology 
2019 
  AVANOVA 
(NCT02354131) Mirza et 
al. Lancet Oncology , 2019
 
Drug Primary outcomes
PFS (months) PARP 
inhibitor v placebo
All patients: 10.8 v 5.4
BRCAmut: 16.6 v 5.4
HRD: 13.6 v 5.4
HRD & BRCAwt: 9.7 v 5.4
HRP: 6.7 v 5.4
gBRCAmut: 21 v 5.5
gBRCAwt: 9.3 v 3.9
HRD & BRCAwt: 12.9 v 3.8
HRP: 6.9 v 3.8
Olaparib 300mg bd tablets (n=196), 
placebo (n=99)
 PFS BRCAmut: 19.1 v 5.5
All patients: 10.8 v 5.4
BRCAmut: 11.2 v 4.3
BRCAwt 7.4 v 5.5
All patients: 22.1 v 16.6
BRCAmut: 37.2 v 21.7
BRCAwt: 18.9 v 16
HRD: 37.2 v17.7
HRD/BRCAwt: 28.1 v 16.6
HRP/uk: 16.9 v 16
All patients: 13.8 v 8.2
HRD: 21.9 v 10.4
HRD/BRCAmut: 22.1 v 10.9
HRD/BRCAwt: 19.6 v 8.2
HRP: 8.1 v 5.4
BRCAmut: 34.7 v 22
HRD: 31.9 v 20.5
BRCAwt: 18.2 v15.1
HRP: 15.0 v 11.5
All patients: 23.5 v 17.3
Niraparib 300mg (n=487) v placebo 
(n=246)
PFS in ITT and HRD 
carboplatin/taxane + maintenance 
placebo (n=375), 
carboplatin/taxane and 
maintenance veliparib (n=383) 
carboplatin/taxane with veliparib 
and maintenance veliparib (n=382)
PFS in veliparib 
throughout group v 
control group  in ITT, 
BRCAmut and HRD 
Rucaparib 600mg bd (n=375) v 
placebo (n=189)
PFS in ITT, HRD (LOH)  and 
BRCAmut group
nce Therapy in Platinum Sensitive Reccurence (>=2 previous lines of platinum based chemot
Olaparib 300mg bd tablets(n=537) 
plus bevacizumab (15mg/kg d1, 
q3w)  v placebo (n= 269) plus 
bevacizumab
PFS in ITT population
Maintenance PARP inhibitor - first-line setting
Niraparib 300mg od (n=372) v 
placebo (n=181)
PFS according to BRCAmut 
status and HRD status 
(Myriad)
Olaparib 400mg bd capsules 
(n=136), placebo (n=129)
PFS analysed by overall 
population and BRCA 
status
Olaparib 300mg bd tablets (n=260), 
placebo (n=131)
PFS in ITT population BRCAmut: NR v 13.8
PFS (months) Combination 
therapy v PARP inhibitor 
All patients: 11.9 v 5.5
BRCAmut: 14.4 v 9.0
BRCAwt: 11.3 v 4.2
HRD & BRCAwt: 11.9 v 4.1
All patients: 16.5 v 8.2
BRCAmut: 16.4 v 16.5







Niraparib 200mg + Pembrolizumab 
200mg IV (n=62) [single arm study]
ORR in ITT population 
cediranib 30 mg daily and olaparib 
capsules 200 mg (n=44) v olaparib 
capsules 400 mg bd (n=46)
PFS in ITT population
Niraparib 300mg + bevacizumab 15 
mg/kg (n=48) v Niraparib 300mg 
(n=49)
































            therapy)
     
0.30 (0.23-0.41)
HR (95% CI)
0·35 (0·21–0·57)
0.49 (0.21-1.15)
0.32 (0.17-0.58)
0.19 (0.06-0.59)
0.50 (0.30-0.83)
0.76 (0.38-1.49)
0.31 (0.15-0.66)
95% CI
95% CI 11-29
95% CI 4-33
95% CI 9-34
95% CI 3-47
95% CI 10-31


